News | April 14, 2014

CardiacAssist Receives Health Canada Approval for TandemHeart Circulatory Support Platform

Percutaneous left ventricular bypass for temporary circulatory support durations up to 10 days now available to Canadian patients

April 14, 2014 — CardiacAssist announced it has received a Class 4 medical device license for its TandemHeart system from Health Canada. The TandemHeart system is now licensed to provide up to 10 days of circulatory support in:

  • Patients with reduced left ventricular function (e.g., post-cardiotomy, low output syndrome, cardiogenic shock after acute myocardial infarction [MI] or from non-ischemic causes); and
  • Patients with limited pre-operative/pre-procedure ejection fraction (EF) and/or with a high risk of post-operative/post-procedure low output syndrome.


“The TandemHeart platform offers a new and unique opportunity for Canadian physicians to effectively treat patients in severe cardiac distress,” said Vladimír Džavík, M.D., FACC, director of interventional cardiology at the Peter Munk Cardiac Center in Toronto. “We are very excited to be able to provide this best-in-class technology to patients facing a condition that has been a significant clinical challenge for decades, and we look forward participating in the development of new clinical science with a focus on improving survival rates.”

When patients experience an acute cardiovascular event, such as a heart attack, the capability of the heart muscle to pump blood is often significantly reduced. If left untreated, the result is a reduction of blood flow to the vital organs that could eventually lead to death. Hospitals with advanced cardiac care capability may treat these patients by initiating circulatory support to augment the flow of blood through the patient’s body. Several alternative circulatory support therapies are available, but the TandemHeart platform provides a unique therapeutic option for Canadian patients presenting to the hospital in severe cardiac distress.

The TandemHeart system can be implanted using a minimally invasive procedure in the cardiac catheterization lab or operating room (OR) by a skilled interventional cardiologist or cardiovascular surgeon. It is the only percutaneous platform able to completely bypass the left ventricle, the pumping chamber of the heart most commonly affected by a heart attack. This is accomplished through a transseptal access procedure to withdraw oxygenated blood from the left atrium, a holding chamber for the left ventricle, and return it to the central arterial circulation. This unique configuration enables the TandemHeart device to take over for the damaged native heart while also allowing the patient’s left ventricle to rest and recover.

“During the course of the approval process we have been very thankful for the guidance of Dr. Vladimír Džavík and several other thought leaders in the cardiovascular space who are committed to bringing the benefits of TandemHeart to patients throughout Canada,” said John Marous, president and CEO of CardiacAssist. “We and all of our physician partners in the Canadian community are very excited to finally be able to bring this technology to market while pushing new frontiers of cardiovascular medicine through investment in clinical science in Canada.”

For more information: www.tandemheart.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD) | May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD) | April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD) | April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD) | March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD) | March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD) | March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init